Keros Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Keros Therapeutics, Inc. (KROS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $900.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-08-03
- Keros Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-06-30 was $700.00K, a 40.00% increase year-over-year.
- Keros Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-03-31 was $200.00K, a 100.00% increase year-over-year.
- Keros Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-12-31 was -$5.00K, a 100.31% decline year-over-year.
- Keros Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-09-30 was $100.00K, a 91.67% decline year-over-year.
- Keros Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $695.00K, a 93.12% decline from fiscal 2024.
- Keros Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $10.10M, a 58.58% increase from fiscal 2023.
- Keros Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $6.37M, a 12.99% increase from fiscal 2022.
- Keros Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $5.64M, a 57.54% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $700.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $900.00K 10-Q · filed 2026-08-03 | $895.00K derived: sum of 3 quarters · filed 2026-08-03 | $995.00K derived: sum of 4 quarters · filed 2026-08-03 | ||
| 2026-03-31 | $200.00K 10-Q · filed 2026-05-14 | $195.00K derived: sum of 2 quarters · filed 2026-05-14 | $295.00K derived: sum of 3 quarters · filed 2026-05-14 | $795.00K derived: sum of 4 quarters · filed 2026-08-03 | ||
| 2025-12-31 | -$5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $95.00K derived: sum of 2 quarters · filed 2026-03-04 | $595.00K derived: sum of 3 quarters · filed 2026-08-03 | $695.00K 10-K · filed 2026-03-04 | ||
| 2025-09-30 | $100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $600.00K derived: sum of 2 quarters · filed 2026-08-03 | $700.00K 10-Q · filed 2025-11-05 | $2.30M derived: sum of 4 quarters · filed 2026-08-03 | ||
| 2025-06-30 | $500.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $600.00K 10-Q · filed 2026-08-03 | $2.20M derived: sum of 3 quarters · filed 2026-08-03 | $3.40M derived: sum of 4 quarters · filed 2026-08-03 | ||
| 2025-03-31 | $100.00K 10-Q · filed 2026-05-14 | $1.70M derived: sum of 2 quarters · filed 2026-05-14 | $2.90M derived: sum of 3 quarters · filed 2026-05-14 | $4.50M derived: sum of 4 quarters · filed 2026-05-14 | ||
| 2024-12-31 | $1.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $2.80M derived: sum of 2 quarters · filed 2026-03-04 | $4.40M derived: sum of 3 quarters · filed 2026-03-04 | $10.10M 10-K · filed 2026-03-04 | $10.13M 10-K · filed 2025-02-26 | |
| 2024-09-30 | $1.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $2.80M derived: sum of 2 quarters · filed 2025-11-05 | $8.50M 10-Q · filed 2025-11-05 | $10.77M derived: sum of 4 quarters · filed 2025-11-05 | ||
| 2024-06-30 | $1.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $7.30M 10-Q · filed 2025-08-06 | $9.57M derived: sum of 3 quarters · filed 2025-08-06 | $9.97M derived: sum of 4 quarters · filed 2025-08-06 | ||
| 2024-03-31 | $5.70M 10-Q · filed 2025-05-06 | $7.97M derived: sum of 2 quarters · filed 2025-05-06 | $8.37M derived: sum of 3 quarters · filed 2025-05-06 | $11.67M derived: sum of 4 quarters · filed 2025-05-06 | ||
| 2023-12-31 | $2.27M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $2.67M derived: sum of 2 quarters · filed 2024-11-06 | $5.97M derived: sum of 3 quarters · filed 2024-11-06 | $6.37M 10-K · filed 2024-02-28 | ||
| 2023-09-30 | $400.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $3.70M derived: sum of 2 quarters · filed 2024-11-06 | $4.10M 10-Q · filed 2024-11-06 | $4.14M derived: sum of 4 quarters · filed 2024-11-06 | ||
| 2023-06-30 | $3.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $3.70M 10-Q · filed 2024-08-07 | $3.74M derived: sum of 3 quarters · filed 2024-08-07 | $5.34M derived: sum of 4 quarters · filed 2024-08-07 | ||
| 2023-03-31 | $400.00K 10-Q · filed 2024-05-08 | $1.30M 10-Q · filed 2023-05-04 | $437.00K derived: sum of 2 quarters · filed 2024-05-08 | $2.04M derived: sum of 3 quarters · filed 2024-05-08 | $5.64M derived: sum of 4 quarters · filed 2024-05-08 | |
| 2022-12-31 | $37.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | $1.64M derived: sum of 2 quarters · filed 2023-11-06 | $5.24M derived: sum of 3 quarters · filed 2023-11-06 | $5.64M 10-K · filed 2023-03-03 | ||
| 2022-09-30 | $1.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $5.20M derived: sum of 2 quarters · filed 2023-11-06 | $5.60M 10-Q · filed 2023-11-06 | $8.59M derived: sum of 4 quarters · filed 2023-11-06 | ||
| 2022-06-30 | $3.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $4.00M 10-Q · filed 2023-08-07 | $6.99M derived: sum of 3 quarters · filed 2023-08-07 | $9.17M derived: sum of 4 quarters · filed 2023-08-07 | ||
| 2022-03-31 | $400.00K 10-Q · filed 2023-05-04 | $3.39M derived: sum of 2 quarters · filed 2023-05-04 | $5.57M derived: sum of 3 quarters · filed 2023-05-04 | $8.62M derived: sum of 4 quarters · filed 2023-05-04 | ||
| 2021-12-31 | $2.99M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-09 | $5.17M derived: sum of 2 quarters · filed 2022-03-09 | $8.22M derived: sum of 3 quarters · filed 2022-03-09 | $13.28M 10-K · filed 2022-03-09 | ||
| 2021-09-30 | $2.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $5.23M derived: sum of 2 quarters · filed 2021-11-04 | $10.29M 10-Q · filed 2021-11-04 | $11.46M derived: sum of 4 quarters · filed 2021-11-04 | ||
| 2021-06-30 | $3.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $8.11M 10-Q · filed 2021-08-05 | $9.28M derived: sum of 3 quarters · filed 2021-08-05 | $10.41M derived: sum of 4 quarters · filed 2021-08-05 | ||
| 2021-03-31 | $5.06M 10-Q · filed 2021-05-06 | $6.24M derived: sum of 2 quarters · filed 2021-05-06 | $7.36M derived: sum of 3 quarters · filed 2021-05-06 | $8.09M derived: sum of 4 quarters · filed 2021-05-06 | ||
| 2020-12-31 | $1.18M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $2.31M derived: sum of 2 quarters · filed 2021-03-25 | $3.03M derived: sum of 3 quarters · filed 2021-03-25 | $3.35M 10-K · filed 2021-03-25 | ||
| 2020-09-30 | $1.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $1.85M derived: sum of 2 quarters · filed 2020-11-10 | $2.17M 10-Q · filed 2020-11-10 | |||
| 2020-06-30 | $723.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | $1.04M 10-Q · filed 2020-08-13 | ||||
| 2020-03-31 | $321.00K 10-Q · filed 2020-05-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |